Candidates: BNT162a1, BNT162b1, BNT162b2, and BNT162c2
Types: Two nucleoside modified mRNA (modRNA) candidates (BNT162a1 and second unspecified candidate); a uridine containing mRNA (uRNA) candidate; and a candidate using self-amplifying mRNA (saRNA). Each mRNA format is combined with a lipid nanoparticle (LNP) formulation. The larger spike sequence is included in two of the candidates, while the smaller optimized receptor binding domain (RBD) from the spike protein is included in the other two candidates.
Status: BioNTech said May 12 that the first clinical data is expected at the end of June or in July from the the Phase I/II clinical trial assessing BNT162 (NCT04368728; EU Clinical Trials Registry EudraCT number 2020-001038-36), which has dosed its first participants in Europe and the U.S.
Twelve participants in Europe were dosed with the first BNT162 vaccine candidate as of April 29. The dose escalation portion of the Phase I/II trial will include approximately 200 healthy subjects between the ages of 18-55 and will target a dose range of 1 µg to 100 µg, aiming to determine the optimal dose for further studies as well as to evaluate the safety…
This News From Feed news.google title “BioNTech, Pfizer, and Fosun Pharma – BNT162 – Genetic Engineering & Biotechnology News”
geico insurance,instant auto insurance quote,get auto insurance online,purchase auto insurance online,auto insurance quotes online,farmers insurance,farm insurance,a car insurance